<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang L</submitter><funding>Bethune Project</funding><funding>Special Project of Medical and Health Personnel in Jilin Province</funding><funding>Special Health Project of Jilin Provincial Finance Department</funding><funding>Special Health Project of Jilin Province</funding><pagination>314</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9235166</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>A growing body of research suggests that methylated genes can be used as early diagnostic markers for cancer. Some studies on methylated Syndecan 2 (SDC2) have shown that it has a great diagnostic ability in colorectal cancer. This meta-analysis was aimed to estimate the diagnostic performance of methylated SDC2 as a potential novel biomarker to screen for the colorectal cancer.&lt;h4>Methods&lt;/h4>Two independent researchers conducted a comprehensive literature search to identify all relevant studies on SDC2 methylation for the diagnosis of colorectal cancer from inception to March 1, 2021. By using STATA and Revman software, the data were analyzed using a Bivariate mixed model. The quality of each study was also evaluated.&lt;h4>Results&lt;/h4>A total of 12 studies comprised of 1</pubmed_abstract><journal>BMC gastroenterology</journal><pubmed_title>Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis.</pubmed_title><pmcid>PMC9235166</pmcid><funding_grant_id>3D518V613429</funding_grant_id><funding_grant_id>No. 2019SCZT026</funding_grant_id><funding_grant_id>No. 2020SCZT061</funding_grant_id><funding_grant_id>No. 419161900018</funding_grant_id><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhang D</pubmed_authors><pubmed_authors>Hao T</pubmed_authors><pubmed_authors>Zhong L</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Xiong X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis.</name><description>&lt;h4>Background&lt;/h4>A growing body of research suggests that methylated genes can be used as early diagnostic markers for cancer. Some studies on methylated Syndecan 2 (SDC2) have shown that it has a great diagnostic ability in colorectal cancer. This meta-analysis was aimed to estimate the diagnostic performance of methylated SDC2 as a potential novel biomarker to screen for the colorectal cancer.&lt;h4>Methods&lt;/h4>Two independent researchers conducted a comprehensive literature search to identify all relevant studies on SDC2 methylation for the diagnosis of colorectal cancer from inception to March 1, 2021. By using STATA and Revman software, the data were analyzed using a Bivariate mixed model. The quality of each study was also evaluated.&lt;h4>Results&lt;/h4>A total of 12 studies comprised of 1</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-19T17:37:43.2Z</modification><creation>2025-04-19T17:37:43.2Z</creation></dates><accession>S-EPMC9235166</accession><cross_references><pubmed>35754025</pubmed><doi>10.1186/s12876-022-02395-7</doi></cross_references></HashMap>